Can well controlled SLE pt taper #Belimumab? Maybe. Single site w 48 pts & over 2 yrs 44% could taper esp if on #plaquenil. This may change my practice but will follow pts closely POS0107 ⁦@RheumNow⁩ #EULAR2021 ⁦@eular_org⁩ https://t.co/8WCrt11ubV

#EULAR2021 OP0133 retinal toxicity with HCQ use. ⬆️ risk: ⭐️Duration 10-14.9 yr (OR 5) ⭐️Duration >15 yr (OR 19) ⭐️Dose >7 mg/kg/d (OR 4.6) ⭐️Cum dose >2000 g Atherosclerosis, age >80 seen in multi-var analysis But didn't have HCQ levels to predict risk @MaxKonigMD @RheumNow https://t.co/DzWWm0U64L

No requirement to stop cDMARDs before surgery. For biologics stop 1 dose before and restart 14 days post op, JAKi stop 7 days before, restart 14 days post op, glucocorticoids >10mg/day increases risk of infection in #rheumatoidarthritis Michael D George #EULAR2021

⬆️prevalence of HCQ retinopathy: Kaiser Permanente 676 pts retrospect study #OP0133 👉6.8% (n=46) had HCQ retinopathy w/ risks: 👉age>80 (OR 3.83) 👉h/o atherosclerosis (OR 2.99), 👉cum. dose >2000 mg (OR 15.8) 👉10-15 yrs use (OR 4.44) 👉>15 yrs (OR 19) #EULAR2021 @rheumnow https://t.co/QA8HHXdnjL

Based on the data, what would you do in a new SLE patient w/LN class IV who is already on a background of GC's+HCQ? @rheumnow @kidneydoc101 @Lupusreference

OP0131: Pooled data from TULIP-1 and TULIP-2 show anifrolumab (anti-IFN receptor Ab) show improvement of rash and arthritis. Shows promise for drug, particularly in subset of pts with high IFN activity #EULAR2021 @RheumNow https://t.co/sddF2NRlEg

Drug-induced ANCA-associated vasculitis: here are the ones to look for👇 - hydralazine - PTU - penicillamine - thiamazole - sofosbuvir - minocycline - carbimazole (but then a few others floating about!) VigiBase data POS0118 #EULAR2021 @RheumNow https://t.co/ujgJAJQeKY

We are truly blessed to live in an era when response to RA treatment is the norm. (our forefathers looking on jealously from their gold and pencillinamine towers!) real-world data from BIOBADASER registry OP0123 #EULAR2021 @RheumNow https://t.co/RuQkK1ZXZv

Novel Results from the @rheum_covid register in #RA patients presented by @jeffsparks #OP0006 Higher risk for patients on rituximab or on JAK inhibitors for hospitalisation & ventilation or death after #COVID19 infection compared to TNFi users. #EULAR2021 @RheumNow https://t.co/40h5zVpxAO